Buy Soma-Max-10



Manufacturer: Maxtreme Pharma
Category: Hormones & Peptides
Substance: Human Growth Hormone
Package: 1 vial of 10IU


Minimum quantity for this product is: 2


Soma-Max-10 191aa Human Growth Hormone kit for sale. Original Soma Max 10 by Maxtreme Pharma is a lyophilized (freeze-dried) white powder packed in a sealed box containing 10 x 10 iu/vials.

Increase protein synthesis, promotes fat loss. Restores damaged cartilage, tendons & joints. Increases libido & energy.

Soma Max 10 is a brand name and is 100% pharmaceutical made in a lic. company. Each batch is tested before sales.

In adults with growth hormone deficiency, Soma Max 10 reduces fat mass, increases muscle mass and improves energy, vitality and subjective well-being. In patients suffering from severe burns, AIDS associated muscle wasting or undergoing major operations Soma Max 10 promotes wound healing attenuates, increases protein-catabolic response and improves whole-body nitrogen condition after operation.

Somatotropin (HGH) is the most abundant hormone produced by the pituitary gland (pituitary is one of the endocrine glands). The pituitary gland is located in the center of the brain. HGH is also a very complex hormone. It is made up of 191 amino acids – making it fairly large for a hormone. In fact, it is the largest protein created by the Pituitary gland. HGH secretion reaches its peak in the body during adolescence. This makes sense because HGH helps stimulate our body to grow. But, HGH secretion does not stop after adolescence. Our body continue to produce HGH usually in short bursts during deep sleep. Human Growth Hormone is known to be critical for tissue repair, muscle growth, healing, brain function, physical and mental health, bone strength, energy and metabolism. In short, it is very important to just about every aspect of our life!

Soma-Max-10 – Somatropin For Injection (Lyophilized)

Somatropin (as well as endogenous GH) binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by IGF-1 produced in the liver and also locally (e.g., skeletal growth, protein synthesis), while others are primarily a consequence of the direct effects of somatropin (e.g., lipolysis)


Pediatric Patients

  • (somatropin [rDNA origin] injection) is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH).
  • [somatropin (rDNA origin) injection] is indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi Syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing
  • [somatropin (rDNA origin) injection] is indicated for the treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years.
  • [somatropin (rDNA origin) injection] is indicated for the treatment of growth failure associated with Turner syndrome.
  • (somatropin [rDNA origin] injection) is indicated for the treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) ≤ -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

  • (somatropin [rDNA origin] injection) is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD) who meet either of the following two criteria:
  • Adult Onset (AO): Patients who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood Onset (CO): Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

Patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults. Confirmation of the diagnosis of adult growth hormone deficiency in both groups involves an appropriate growth hormone provocative test with two exceptions: (1) patients with multiple other pituitary hormone deficiencies due to organic disease; and (2) patients with congenital/genetic growth hormone deficiency.


Unit Vial with carton & 10 vials per carton